Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

[1]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[2]  D. Neuberg,et al.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.

[3]  C. Preudhomme,et al.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.

[4]  L. Pleyer,et al.  Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group , 2014, Annals of Hematology.

[5]  Marcel J T Reinders,et al.  Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. , 2014, Blood.

[6]  H. Dombret,et al.  Azacitidine in untreated acute myeloid leukemia: A report on 149 patients , 2014, American journal of hematology.

[7]  E. Vellenga,et al.  Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. , 2013, Leukemia research.

[8]  A. Levis,et al.  Azacitidine for the treatment of patients with acute myeloid leukemia , 2012, Cancer.

[9]  R. Arceci.  Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia , 2012 .

[10]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[11]  R. Arceci.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011 .

[12]  K. Döhner,et al.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[14]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[15]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.